Clinical Trial Update: Study of Surufatinib as Second-line Treatment in Patients With Biliary Tract Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating surufatinib as second-line therapy in biliary tract cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Biliary Tract Cancer

Drugs mentioned

• Surufatinib (Surufatinib)

Snippet

Sponsor: Hutchison Medipharma Limited | Conditions: Biliary Tract Cancer | Phase 2 | Status: COMPLETED